Novacyt drops on profit taking, contract extension uncertainty
Last year's best performing stock, specialist clinical diagnostics firm Novacyt (NCYT:AIM), said on Friday full-year revenues to 31 December 2020 increased over 20 times to €311.6 million.The shares fell around 11% to 948p on...
29 January 2021
